Beckner: House Bill 1121 not what it appears |

Beckner: House Bill 1121 not what it appears

House Bill 1121 in the Colorado Legislature is being sold as a way to bring down the price of a certain classification of drugs called “biosimilars;” it’s not.

HB 1121 is an attempt to pre-empt the U.S. Food and Drug Administration (FDA) on biosimilar products. We should be more concerned about protecting the public health by ensuring the safety, efficacy and security of human and veterinary drugs, biological products and medical products by the FDA before they go to market.

HB 1121 is a complicated and confusing bill by design. It is being promoted by two drug companies that want to impede the ability of the market to develop less expensive options of some important medications.

The big question is why Colorado would want to get involved in an issue when the FDA is still considering its options. We have a process that must be followed. Why would we legislate something that doesn?t even exist yet?

Jack Beckner, Dillon

Support Local Journalism

Support Local Journalism

As a Summit Daily News reader, you make our work possible.

Now more than ever, your financial support is critical to help us keep our communities informed about the evolving coronavirus pandemic and the impact it is having on our residents and businesses. Every contribution, no matter the size, will make a difference.

Your donation will be used exclusively to support quality, local journalism.

For tax deductible donations, click here.

Start a dialogue, stay on topic and be civil.
If you don't follow the rules, your comment may be deleted.

User Legend: iconModerator iconTrusted User